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Short summary:  
In this cross-sectional sub-study of a large randomised controlled clinical trial, 
monotherapy with protease inhibitor showed no excess risk of cognitive impairment 
compared to standard cART in stable HIV+ patients. We observed no difference between 
arms on neuroimaging markers either.  
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Abstract  
 
Objective: To determine whether treatment with ritonavir-boosted protease inhibitor 
(PI) monotherapy is associated with detrimental effects on neurocognitive function or 
brain imaging markers compared to standard antiretroviral therapy (ART).  
 
Methods: Neuropsychological assessment and brain magnetic resonance imaging were 
performed at the last study visit in a subset of participants randomised to PI 
monotherapy (PI-mono group) or ongoing triple ART (OT group) in the PIVOT trial. We 
calculated a global z-score (NPZ-7) from the average of the individual test z-scores and 
the proportion of participants with symptomatic neurocognitive impairment (score >1 
standard deviation (SD) below normative means in ≥2 cognitive domains and 
neurocognitive symptoms). In a subgroup, white matter hyperintensities, bicaudate 
index, global cortical (GCA) and medial temporal lobe atrophy scores and single voxel 
(basal ganglia) N-acetylaspartate (NAA)/Choline, NAA/Creatine and myo-
inositol/Creatine ratios were measured.  
 
Results: 146 participants (75 PI-mono) had neurocognitive testing (median time after 
randomisation 3.8 years), of whom 78 were imaged. We found no difference between 
arms in NPZ-7 score (median -0.4 (Interquartile range (IQR)=-0.7; 0.1) vs -0.3 (IQR=-0.7; 
0.3) for the PI-mono and OT groups respectively, p=0.28), the proportion with 
symptomatic neurocognitive impairment (13% and 18% in the PI-mono and OT groups 
respectively; p=0.41), or any of the neuroimaging variables (p>0.05). Symptomatic 
neurocognitive impairment was associated with higher GCA score (OR=6.2 per additional 
score; 95% confidence interval (CI)=1.7-22.3 p=0.005) but no other imaging variables.  
 
Conclusions: Based on a comprehensive neuropsychological assessment and brain 
imaging, PI monotherapy does not increase the risk of neurocognitive impairment in 
stable HIV+ patients.  
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Introduction  
 
Neurocognitive impairment (NCI) is frequently reported in HIV-infected patients, with 
prevalence figures ranging between 40 and 60%, even after prolonged and effective viral 
suppression with combination anti-retroviral therapy (cART)(1-4). It has been suggested 
that different treatment strategies may have differential effect on viral replication in the 
central nervous system (CNS) and therefore, some regimens may be less effective in 
preventing the development or progression of NCI (5-7).  
 
Ritonavir (RTV)-boosted protease inhibitor (PI) monotherapy has been explored as a 
simplification strategy in effectively suppressed, ART-experienced patients in a number 
of randomised controlled trials (RCT)(8). Given that PI monotherapy includes only one 
active drug compared to three in standard cART regimens, the possibility of persistent 
viral replication within the CNS that could lead to progression of neurological 
complications, including NCI, has been expressed as a concern with this approach(9). 
Although the PIVOT trial found no evidence of accelerated neurocognitive function 
decline in participants on PI monotherapy compared to cART over 3-5 years of follow-up, 
this was based on a testing with simple battery of neuropsychological tests designed to 
be suitable for repeated use in large numbers of participants(10).  
 
The aim of this sub-study was to look in more detail for evidence of neurocognitive 
impairment or neuroimaging abnormalities in patients taking PI monotherapy compared 
to patients on standard cART using a more comprehensive neuropsychological testing 
battery and brain magnetic resonance imaging (MRI/MRS).  
 
Methods  
 
PIVOT was a non-inferiority, randomised parallel-group trial (ISRCTN-04857074), 
conducted in 43 sites in the United Kingdom between 2008 and 2013, where 587 
effectively suppressed (viral load <50 copies/mL) HIV-positive adults on cART (two 
nucleoside reverse transcriptase inhibitors (NRTIs) and one non-NRTI (NNRTI) or PI) were 
randomly assigned 1:1 to maintain ongoing triple therapy (OT) or switched to PI-mono. 
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All licensed PIs were allowed, but ritonavir-boosted darunavir (DRV/r) 800mg/100mg 
once daily or ritonavir-boosted lopinavir (LPV/r) 400mg/100mg twice daily were 
recommended. The primary outcome was loss of future drug options, defined as new 
intermediate/high level resistance to drugs in contemporary use to which the patient’s 
virus was considered to be sensitive at trial entry. Neurocognitive function was assessed 
in all study participants with a brief neuropsychological testing battery at baseline, week 
12 and annually thereafter until the end of the study period.  
 
This sub-study was done at 5 of the larger sites of the PIVOT trial, and offered to all 
participants attending the final PIVOT study visit. In addition to the standard PIVOT 
neurocognitive testing battery (comprising the Hopkins Verbal Learning Test-Revised 
(HVLT-R)(11), Color Trail tests 1 and 2 (CTT-1 and CTT-2)(12) and the Grooved Pegboard 
test (GPT)(13)), participants underwent additional tests: Rey Complex Figure Test 
(RCFT)(14), Stroop Color and Word Test (SCWT)(15), Finger Tapping Test (FTT)(16) and 
the WAIS-III Digit Symbol-Coding test (DST)(17) to ascertain function on the 
attention/psychomotor speed, executive functioning, fine motor skills and verbal and 
non-verbal learning and memory cognitive domains.  
 
The presence of cognitive symptoms was assessed from responses to the relevant 
questions (attention, concentration, memory, problem solving or decision making within 
the past four weeks) on the MOS-HIV questionnaire performed at the last study visit  and 
participants were considered symptomatic if responded “a good bit of the time” or more 
often to any of the questions (18). In addition participants were asked about alcohol 
consumption (AUDIT questionnaire(19)), recreational drug use and self-reported anxiety 
/ depression (responses to the relevant question on EQ-5D(20)).  
 
 
Neuroimaging investigations 
 
Multimodal magnetic resonance imaging/spectroscopy (MRI/MRS) of the brain was 
performed using a 3 Tesla Philips Achieva System (Best, Netherlands) at the Institute of 
Neurology, UCL in a single scan session. Seven pre-defined measures were obtained 
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from the scans:  1) total volume of white matter hyperintensities, calculated from hand-
drawn regions of interest (ROI) on a high-resolution 3D fluid-attenuated inversion 
recovery (FLAIR) sequence(21). 2) N-acetylaspartate to choline ratio (NAA/Cho), 3) N-
acetylaspartate to creatine ratio (NAA/Cr) and 4) Myo-inositol to creatine ratio (mI/Cr) of 
the left basal ganglia, as found using the MR spectroscopy (MRS) data of a single 
voxel(22). Finally, 5) Global Cortical atrophy score (GCA)(23), 6) Medial Temporal Lobe 
atrophy score (TLA)(23) and the 7) Bicaudate Index, defined as the ratio of width of both 
lateral ventricles at the level of the caudate nucleus to the distance between outer 
tables of skull at the same level(24). Scans were analysed by individuals who were 
blinded to the participants’ treatment allocation.    
 
Sample size calculation 
 
The hypothesis was that PI monotherapy is not inferior to cART on the NPZ-7 score. We 
assumed no difference in mean NPZ-7 between the two randomisation arms, and that a 
difference of ≤0.4 between arms could be regarded as non-inferior. A sample size was 
calculated to give 80% power to exclude a difference of greater than 0.4 between the 
arms (2-sided α=0.05) (assuming a standard deviation of 0.8, based on the variation of 
the NPZ-5 score in the main PIVOT trial at baseline(25). The sample size for MRI scans 
was limited due to feasibility and funding constraints.  
 
Statistical analysis 
 
Raw scores for each cognitive test were transformed to z-scores using the 
manufacturers’ normative data adjusted for age (all tests) and years of education (CTT, 
SCWT). For the GPT and FTT, the z-scores for the dominant and non-dominant hands 
were averaged. The SCWT was scored as average of word, color, and color-word sub-
tests. Cognitive domain z-scores were calculated by averaging the scores of the relevant 
tests when appropriate. NPZ-7 scores were then calculated by averaging all 7 cognitive 
domains. For all individual test z-scores and the NPZ-7, values below zero denote below-
average neurocognitive function compared to the reference population. For the 
purposes of group comparisons, we defined neurocognitive impairment as a z-score <-1 
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of the normative mean in at least two cognitive domains (similar to the Frascati 
definition of NCI)(26). Symptomatic neurocognitive impairment was defined as 
neurocognitive impairment with reported symptoms (an answer of “a good bit of the 
time” or worse to any of the four components of question 10 (assessing problem solving 
and decision-making, memory, attention and concentration) of the MOS-HIV QoL 
questionnaire) (27). A sensitivity analysis was performed assuming verbal and non-verbal 
learning and verbal and non-verbal memory are expression of the same cognitive 
domains resulting in a sub-study NPZ-5 with two tests for each domain. 
 
Primary analyses were according to intention to treat (ITT). Additional sensitivity 
analyses were performed based on actual treatment taken. Proportions were compared 
using chi-square or Fisher’s exact tests as appropriate. Continuous test scores were 
compared using t-test or Mann-Whitney rank tests. Multivariable logistic, ordered 
logistic and linear regression models were used to examine associations with 
neurocognitive impairment and the following variables: gender, age, ethnicity, years of 
education, nadir and current CD4+ T-cell count, time known HIV+, current and past 
smoking and use of recreational drugs and alcohol. Correlations between individual test 
z-scores within each cognitive domain were explored using Pearson coefficient. 
Moderate correlation was defined based on coefficients ranging from 0.4 to 0.6 whereas 
coefficients >0.6 were considered evidence of strong correlations. 
 
The main PIVOT protocol and this sub-study protocol were approved by the 
Cambridgeshire 4 Research Ethics Committee and all relevant R&D offices. All 
participants provided written informed consent. 
 
 
Results  
 
Study population 
Of 219 PIVOT participants who attended their final trial visit (median 3.8 years from 
randomisation) at the 5 participating sites, 146 (67%) (75 PI-mono, 71 OT) were enrolled 
in the sub-study (Fig 1). Enrolled participants were older and more commonly had VL 
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suppression (<50 copies/ml) than those who were not enrolled at the sites 
(Supplementary Table 1).  
 
Sub-study participants were mainly white men, with a median of 15 years formal 
education, and substantial rates of self-reported anxiety / depression (32%), smoking 
(24%), risky alcohol consumption (36%) and current recreational drug use (31%) (Table 1, 
supplementary Table 2a and 2b). Participants in the PI-mono group were older (mean 49 
versus 46 years; p=0.022), and fewer were cigarette smokers (15% versus 34%; p=0.01) 
compared to those in the OT group (Table 1). At the time of the sub-study visit, 49 (65%) 
of those in the PI-mono group were taking PI-monotherapy (41 DRV/r, 6 LPV/r, 2 
atazanavir (ATV/r)) and 4 in the PI-group and 12 in the OT group were taking efavirenz.  
 
Neurocognitive function 
 
We found no difference between the groups in the median z-score on any individual test 
or cognitive domain (Table 2). There was also no difference between study groups in 
summary NPZ-7 score (-0.4 in the PI-mono group vs -0.3 in the OT group; p=0.25; 
difference 0.14 (95% CI -0.10 to 0.39); non-inferiority criterion formally met). 
Furthermore, we found no difference between groups when average z-score on the 
PIVOT short battery (NPZ-5; p=0.31) or the additional four sub-study tests (p=0.20) were 
compared separately. There also was no relationship between randomised arm and NPZ-
7 score in multivariable regression analyses; the only independent associations with the 
lower NPZ-7 score were older age and black ethnicity (Table 3). The results were 
unchanged in sensitivity analyses based on treatment taken at the time of the sub-study, 
or using sub-study NPZ-5 as outcome instead of NPZ-7. 
 
Moderate correlation was observed between tests measuring the same cognitive 
domain, except in the case of tests measuring fine motor skills. Similarly, there was 
strong correlation between tests measuring verbal learning and memory and non-verbal 
learning and memory (Supplementary table 3). 
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Considering the whole sub-study population, there were no differences between the 
groups in the proportion of participants with overall neurocognitive impairment (45% in 
the PI-mono vs 49% in the OT group; p=0.63) or in the proportion of participants with 
symptomatic neurocognitive impairment (13% in the PI-mono vs 18% in the OT group; 
p=0.41; Table 2).  There also was no association between study arm and overall 
neurocognitive impairment or symptomatic neurocognitive impairment using logistic 
regression adjusting for age, ethnicity, education and nadir CD4 count . The only 
significant association with overall neurocognitive impairment was with black ethnicity 
(OR=5.5; 95%CI 1.8-16.2; p=0.002); there were no significant associations found with 
symptomatic neurocognitive impairment.  
 
Neuroimaging markers  
 
Brain MRI/MRS was performed in 78 of the 146 sub-study participants (53%, 39 on each 
study arm). There were no differences between participants with and without 
neuroimaging in any of the measured variables (Supplementary table 4). We found no 
differences between arms in any of the neuroimaging measures (Table 4). No 
associations were found between any of the neuroimaging measures and test-specific, 
domain or global (NPZ-7) z-scores (data not shown) or the presence of overall 
neurocognitive impairment (Table 5).  
 
We also did not find any association between neuroimaging measures and the presence 
of symptomatic neurocognitive impairment, apart from GCA where we found a higher 
risk with increasing scores (OR 6.2; 95% CI 1.7-22.3; p=0.005) (Table 5). However, further 
analyses suggested that this was driven by the significant association of GCA scores with 
neurocognitive symptoms irrespective of neurocognitive test performance. 
 
Discussion  
 
Our findings support the results of the main PIVOT trial that found no difference in 
neurocognitive function between PI monotherapy and triple therapy arms over 3-5 years 
of follow-up (also consistent with 48 week changes in another PI monotherapy trial)(10, 
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28). The findings of this sub-study strengthen the earlier conclusions by extending the 
neurocognitive assessment to include a more comprehensive neuropsychological testing 
battery than the brief one used for longitudinal assessment in these trials, which would 
be expected to be more sensitive in detecting between-group differences if they existed. 
In particular, the sub-study battery included two different tests to measure some of the 
cognitive domains explored (i.e. attention-concentration, executive functioning and fine 
motor skills) which is recommended (26). In addition, we added tests to explore non-
verbal learning and memory, which are domains less likely to be affected by unmeasured 
cultural factors(25). We also collected additional information on comorbid conditions 
such as alcohol or recreational drugs use and mood disorders to allow analyses to be 
adjusted for these important factors.    
 
The consistent results in this sub-study between the expanded battery and the short 
battery (used in the main trial) also lend confidence to the validity of neurocognitive 
testing results reported for the main trial. Extensive and detailed longitudinal 
investigation of neurocognitive function in large, multi-centre, strategy, randomised 
controlled trials would have been very difficult to implement and extremely onerous. 
Therefore, more pragmatic approaches, as the one we implemented in PIVOT, are 
probably more appropriate. 
 
The proportion of sub-study participants that met the definition of impairment used for 
this study was high (45%). However, the proportion of participants meeting the criteria 
for symptomatic neurocognitive impairment, a more relevant clinical endpoint (29, 30), 
was much lower (15.8%). The absence of between-group differences on the 
neurocognitive tests, whether based on a composite z-score or on a threshold 
classification, as well as the absence of differences on neuroimaging investigations lends 
support to the conclusion from the main PIVOT trial (and other studies) that there is no 
added risk from PI monotherapy (28, 31).  
 
Different neuroimaging techniques have been used to identify markers of HIV-associated 
neurocognitive impairment, including magnetic resonance spectroscopy (MRS), and the 
effect of different treatment options on these markers has been explored in treatment 
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naïve patients starting cART(32). However, information on effectively suppressed 
patients is lacking, and in particular there are very limited data comparing neuroimaging 
markers between patients on PI monotherapy and cART(33). 
 
Consistent with our results, associations between imaging markers of cerebral atrophy 
and neurocognitive impairment have been previously reported in both naïve and ART-
experienced patients (34-36). However, in our study, the association between an 
atrophy measurement, higher GCA score, and cognitive function was limited to those 
with symptomatic impairment. Conversely, cortical atrophy has also been described in 
patients with long-term HIV disease with normal cognitive function (37) whereas 
symptomatic neurocognitive impairment has been associated with longer duration of 
both HIV disease and exposure to cART (38). Our participants were very ART-
experienced patients and free from virological failure (at baseline) but cognitive 
symptoms were not infrequent (23%). However, we found no association between any 
HIV or ART-related variables and neurocognitive function, symptoms or neuroimaging 
measurements. 
 
Our study has some limitations. The sub-study recruited a subset of randomised 
participants (67% of those at the participating sites). Although there is the possibility of 
selection bias, the overall similarity of those recruited to the overall trial population at 
the sites (minor differences in age and proportion with VL suppression below 50 
copies/ml) suggests this is unlikely to have had an important effect. Furthermore, the 
fact that neurocognitive results in this sub-study are consistent with the results of the 
main trial (no differences between treatment arms) also strengthens confidence in their 
validity. Participants in clinical trials generally tend to be highly selected and this may 
impact generalisability. This may be the case in this trial and sub-study, since in PIVOT all 
participants were free of previous episodes of virological failure suggesting high level of 
adherence to their ART and the prevalence of comorbid conditions likely to affect 
cognition, such hepatitis C co-infection or CNS opportunistic infections was very low. 
However, the study population was very homogeneous and therefore ideal to assess 
cognitive function in effectively suppressed patients with no major comorbidities. The 
criteria used to define neurocognitive symptoms and the definition of neurocognitive 
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impairment we used were somewhat arbitrary, but that we considered appropriate for 
the population studied based on the available data collected in the main trial. In 
addition, a similar threshold approach is commonly used. (39-41). Alternative thresholds 
might give different overall proportions of patients classified as neurocognitively 
impaired, but this is of less relevance for this study which focuses on the comparison of 
treatment groups. The conclusions were the same, whether the analyses were based on 
this threshold approach or on composite z scores.  The cross-sectional study design is 
also a limitation for the neuroimaging component since we have no baseline imaging 
and could not assess any difference between arms in change over time.   
 
In summary, using a comprehensive neuropsychological testing battery, this analysis 
confirms previous observations made using brief testing batteries showing no excess risk 
of cognitive impairment in patients on PI-mono compared to standard cART(10, 28). The 
absence of differences between arms on detailed MRI/MRS analysis also supports the 
earlier conclusion that PI-monotherapy does not carry a substantive risk of CNS damage 
and should give confidence to patients and physicians who wish to use this therapeutic 
option for long-term management of HIV infection.  
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Table 1. Characteristics of sub-study participants by randomisation arm 
    
   
PI-mono 
(N=75) OT (N=71) p Overall (N=146) 
Age, Mean (SD) 49 (9) 46 (8) 0.02 48 (9) 
Sex, N (%)     
          Male 63 (84.0) 63 (88.7) 0.41 126 (86.3) 
Ethnicity, N (%)      0.41   
         White 58 (77.3) 61 (85.9)  119 (81.5) 
         Black 14 (18.7) 8 (11.3)  22 (15.1) 
         Other 3 (4.0) 2 (2.8)  5 (3.4) 
Years of formal education,  
Median (IQR) 15 (12 - 18) 15 (13 - 18) 0.53 15 (12 - 18) 
CD4 cell count nadir, Median (IQR) 170 (90 - 250) 191 (100 - 269) 0.41 180 (90 - 260) 
CD4 cell count at entry, Median 
(IQR) 621 (467 - 760) 650 (540 - 830) 0.27 640 (483 - 785) 
HIV-RNA <50 copies/ml, N (%) 72 (96.0) 67 (95.7) 1.00 139 (95.9) 
Risky alcohol consumption, N (%)1 22 (29.3) 30 (42.9) 0.09 52 (35.9) 
Recreational drugs use, N (%) 
          In the past 
          Currently 
26 (35.1) 
25 (33.8) 
30 (44.1) 
19 (27.9) 
0.54 
56 (39.4) 
44 (31.0) 
Smokers at sub-study visit, N (%) 11 (14.7) 24 (33.8) 0.01 35 (24.0) 
Depression/anxiety2 
          Moderate 
          Severe 
24 (34.8) 
2 (2.9) 
20 (29.4) 
4 (5.9) 
0.63 
44 (32.1) 
6 (4.4) 
Neurocognitive symptoms 3 
            
17 (23.0) 16 (22.5) 0.95 17 (23.0) 
ART exposure at sub-study visit 
           2NRTI + 1NNRTI 
           2NRTI + 1PI 
           PI monotherapy 
           Other ART combination 
           Off ART 
9 (12.0) 
15 (20.0) 
49 (65.3) 
2 (2.7) 
0 (0.0) 
22 (31.0) 
40 (56.3) 
5 (7.0) 
3 (4.2) 
1 (1.4) 
<0.001 
31 (21.2) 
55 (37.7) 
54 (37.0) 
5 (3.4) 
1 (0.7) 
1 Based on AUDIT questionnaire score 
2 Based on EQ-5D Health Status questionnaire  
3 Based on MOS-HIV QoL questionnaire 
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Table 2. Neurocognitive function and impairment by study arm  
Results presented as z-scores median (IQR) unless otherwise stated. 
¶ P-values from t-test or chi2-test. 
*PIVOT neuropsychological testing battery 
‡ Sub-study testing battery: Considering verbal and non-verbal learning and verbal and 
non-verbal memory measures of the same comains. 
¥Neurocognitive impairment: defined as z-score <-1 in ≥2 cognitive domains 
 
 
 
 
 
 
 
 
 
  PI-mono  OT p¶ Overall 
Attention/concentration            
Color Trails Test- Part 1*  0.3 (-0.3, 0.9) 0.5 (-0.2, 0.9) 0.86 0.4 (0.2, 0.9 ) 
Symbol-digit test -0.7 (-1.0, 0.3) 0.0 (-0.7, 0.7) 0.10 -0.3 (-1.0, 0.3) 
Executive functioning   
Color Trails Test- Part 2*  0.8 (0.2, 1.3) 0.9 (0.5, 1.3) 0.84 0.9 (0.3, 1.3) 
Stroop colour-word test -0.7 (-1.6, 0.2) -0.3 (-1.0, 0.4) 0.16 -0.5 (-1.2, 0.3) 
Fine motor skills  
Grooved Pegboard Test: both hands*  -0.1 (-0.8, 0.6)  0.1 (-0.9, 0.6) 0.25 0.0 (-0.9, 0.6) 
Finger tapping: both hands -1.8 (-2.5, -0.8) -1.6 (-2.2, -0.8) 0.86 -1.8 (-2.5, -0.8) 
Verbal learning   
Hopkins Verbal Learning test (Revised)* -0.4 (-1.2, 0.1)  -0.1 (-1.0, 0.7) 0.45 -0.3 (-1.2, 0.4) 
Verbal  memory    
Hopkins Verbal Learning test (Revised)*  0.0 (-1.1, 0.8)  -0.1 (-1.0, 0.9) 0.33 -0.1 (-1.0, 0.9) 
Non-verbal learning        
Rey Complex Figure test -0.4 (-0.8, 0.3) -0.2 (-1.4, 0.7) 0.69 -0.4 (-1.2, 0.6) 
Non-verbal memory  
Rey Complex Figure test -0.4 (-1.1, 0.2) -0.5 (-1.5, 0.7) 0.98 -0.4 (-1.3, 0.5) 
Summary z-scores  
PIVOT summary Z-score (NPZ-5)*  0.1 (-0.5, 0.6) 0.2 (-0.3, 0.6) 0.31 0.1 (-0.4, 0.6) 
Sub-study summary Z-score (NPZ-7) -0.4 (-0.7, 0.1) -0.3 (-0.7, 0.3) 0.25 -0.3 (-0.7, 0.2) 
Sub-study summary Z-score (sNPZ-5)‡  -0.3 (-0.8, 0.0) -0.3 (-0.7, 0.3) 0.23 -0.3 (-0.7, 0.2 ) 
Neurocognitive impairment¥, N (%)  
Symptomatic  10 (13.3) 13 (18.3) 0.41 23 (15.8) 
Overall 34 (45.3) 35 (49.3) 0.63 69 (47.3) 
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Table 3. Factors associated with global neurocognitive score (NPZ-7), defined as the 
average z-score across seven cognitive domains: Linear regression models  
 
 Coef. 95% CI p 
PI-mono -0.00 -0.24, 0.23 0.989 
Age (per 10 additional years) -0.16 -0.31, -0.02 0.024 
Female gender -0.19 -0.65, 0.28 0.421 
Ethnicity (black) -0.71 -1.17, -0.25 0.003 
Education (per additional 
year) 
 0.02 -0.02, 0.06 0.409 
Risky alcohol consumption¥  0.20 -0.04, 0.45 0.102 
Recreational drugs use    
In the past -0.14 -0.45, 0.17 0.372 
Current use  0.08 -0.25, 0.41 0.649 
Smoking    
In the past  0.04 -0.23, 0.32 0.751 
Current use -0.05 -0.37, 0.27 0.758 
¥ AUDIT questionnaire score: Hazardous or harmful consumption and likely dependency 
 
 
 
 
 
 
 
Table 4. Neuroimaging markers by study arm  
 
  PI-mono (n=39) OT (n=39) p 
WMH  
   WMH present, N (%) 22 (56.4) 25 (64.1) 0.64 
Volume (mm3), median (IQR) 76 (0 – 667) 101 (0 – 347) 0.91 
Atrophy measures    
GCA score, median (IQR) 1 (0 – 2) 1 (1 – 1) 0.60 
TLA score, median (IQR) 1 (1 – 2) 1 (1 – 1) 0.77 
Bicaudate index, median (IQR) 0.11 (0.10 – 0.13) 0.10 (0.09 – 0.12) 0.07 
Single Voxel MRS    
NAA/Ch, median (IQR) 4.2 (3.9 – 4.8) 4.4 (4.0 – 4.7) 0.37 
NAA/Cr, median (IQR) 1.0 (0.9 -1.0) 1.0 (0.9 – 1.0) 0.53 
mI/Cr, median (IQR) 0.6 (0.5 – 0.7) 0.5 (0.5 – 0.6) 0.56 
WMH: White matter hyperintensities; GCA: Global cortical atrophy score; TLA: Medial 
temporal lobe atrophy score; NAA/Ch: N-acetyl aspartate to choline ratio; NAA/Cr: N-
acetyl aspartate to creatine ratio; mI/Cr: Myo-inositol to creatine ratio. 
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Table 5. Association between imaging measurements and neurocognitive impairment, 
defined as a z-score <-1 in at least two out of seven cognitive domains: Logistic 
regression models*  
 
 Overall Neurocognitive 
Impairment  
 
Symptomatic  Neurocognitive 
Impairment 
OR 95% CI p OR 95% CI p 
White Matter 
Hyperintensities 
      
Lesion Volume (log10) ¥ 1.0 0.9, 1.1 0.857 1.1  1.0, 1.2 0.266      
Atrophy scores       
GCA 1.2 0.6, 2.7 0.580 6.2    1.7, 22.3 0.005      
TLA 1.3 0.6, 2.7 0.515 1.8  0.8, 4.4 0.173      
Bicaudate index 1.1 0.6; 2.2 0.737 2.0 0.9, 4.4 0.100 
Single Voxel MRS       
NAA/Ch¥ 1.2 0.6, 2.6 0.590 1.9  0.8, 4.5 0.140       
NAA/Cr¥ 1.7 0.8, 3.4 0.164 1.9   0.9, 4.3 0.116      
mI/Cr¥ 1.0 0.5, 1.8 0.953 0.8    0.4, 1.5 0.454      
*Adjusted for study arm allocation, age (per additional year), ethnicity (black vs other), 
education (per additional year on formal education) and nadir CD4 count (per 100c 
more) 
GCA: Global cortical atrophy score; TLA: Medial temporal lobe atrophy score; NAA/Ch: N-
acetyl aspartate to choline ratio; NAA/Cr: N-acetyl aspartate to creatine ratio; mI/Cr: 
Myo-inositol to creatine ratio. 
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